The new face of Comprehensive reflects the Company’s diverse therapeutic expertise and suite of clinical services. Articulating Comprehensive’s depth and breadth in therapeutic expertise with the rebrand, Comprehensive’s unwavering commitment to both its internal and external customers remains.
During the DIA Annual Meeting, Royce A. Morrison, M.D., M.S., Comprehensive Clinical Development’s chief medical officer, will present his findings on technology in early phase studies and strategies to optimize the methods utilized. His presentation, Track 4 (A), titled, “Nonclinical and Early Clinical Translational Development,” is scheduled for Wednesday, June 22, from 1:30 – 3:00 p.m.
“We are looking forward to launching our new brand at DIA,” stated Comprehensive Clinical Development CEO Jack McGovern. "Our new branding identity reflects who we are as a company and better positions us as a pivotal partner in accessing patients and managing complex studies, providing our clients with a sense of confidence in Comprehensive.”
About Comprehensive Clinical Development
Comprehensive Clinical Development is a strategic clinical research partner providing a full range of clinical services in various therapeutic areas with an outstanding record for consistently delivering quality and success on time and within budget. Comprehensive holds a solid track record of collecting early efficacy data across various patient populations, and offers distinct capabilities in clinical research. For more information about Comprehensive, visit www.ComprehensiveCD.com.
